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ABSTRACT 
Objectives 
In airway infections, biofilm formation has been demonstrated to be responsible for both 
acute and chronic events, and constitutes a genuine challenge in clinical practice. Difficulty 
in eradicating biofilms with systemic antibiotics has led clinicians to consider the possible 
role of non-antibiotic therapy. The aim of this review is to examine current evidence for the 
use of N-acetylcysteine (NAC) in the treatment of biofilm-related respiratory infections. 
Methods 
Electronic searches of PUBMED up to September 2015 were conducted, searching for 
‘biofilm’, ‘respiratory tract infection’, ‘N-acetylcysteine’, ‘cystic fibrosis’, ‘COPD’, 
‘bronchiectasis’, ‘otitis’, and ‘bronchitis’ in titles and abstracts. Studies included for review 
were primarily in English, but a few in Italian were also selected. 
Results 
Biofilm formation may be involved in many infections, including ventilator-associated 
pneumonia, cystic fibrosis, bronchiectasis, bronchitis, and upper respiratory airway 
infections. Many in vitro studies have demonstrated that NAC is effective in inhibiting 
biofilm formation, disrupting preformed biofilms (both initial and mature), and reducing 
bacterial viability in biofilms. There are fewer clinical studies on the use of NAC in 
disruption of biofilm formation, although there is some evidence that NAC alone or in 
combination with antibiotics can decrease the risk of exacerbations of chronic bronchitis, 
chronic obstructive pulmonary disease, and rhinosinusitis. However, the usefulness of 
NAC in the treatment of cystic fibrosis and bronchiectasis is still matter of debate. Most of 
the studies published to date have used oral or intramuscular NAC formulations. 
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Conclusions 
Evidence from in vitro studies indicates that NAC has good antibacterial properties and the 
ability to interfere with biofilm formation and disrupt biofilms. Results from clinical studies 
have provided some encouraging findings that need to be confirmed and expanded using 
other routes of administration of NAC such as inhalation.  
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Introduction 
Bacteria can exist as single, independent cells (planktonic) or can be organized into 
sessile aggregates called biofilms. A biofilm is a structured community of bacterial cells 
enclosed in a self-produced polymeric matrix and adherent to an inert or living surface. 
Acute infections are assumed to involve planktonic bacteria, which are generally treatable 
with antibiotics, although successful treatment depends on accurate and fast diagnosis, 
and treatment with an appropriate antibiotic. However, in cases where the bacteria 
succeed in forming a biofilm within the human host, the infection is often resistant to 
standard treatment regimes and will therefore develop into a chronic state. Recent 
advances have demonstrated that biofilms account for most human infections [1,2] and are 
related to exacerbation or relapse of symptoms. Characteristic features of chronic biofilm-
based infections are increased resistance to host defenses and decreased susceptibility to 
antimicrobial agents. These features make persistent infections difficult or impossible for 
the immune system to clear and to be eradicated with antibiotics [2, 3].  
In airway infections, biofilm formation has been demonstrated to be responsible for both 
acute and chronic events and is a real challenge in clinical practice [1,2]. The observation 
that systemic antibiotics are not unequivocally effective in eradicating biofilms has led to 
an increased interest in non-antibiotic therapies. In this review, we discuss the role of 
biofilms in respiratory infections and current management strategies, focusing on the 
current evidence regarding the effects of NAC on biofilms. 
 
Literature search methodology 
Literature searches, conducted in the period August-September 2015, were performed 
using the PubMed database (with no date limitations), searching with the terms ‘biofilm’, 
‘respiratory tract infection’, ‘N-acetylcysteine’, ‘cystic fibrosis’, ‘COPD’, ‘bronchiectasis’, 
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‘otitis’, and ‘bronchitis’ in titles and abstracts, and restricting the results primarily to articles 
written in English. A few publications in Italian were also included. The authors examined 
the resulting lists of abstracts and excluded those that did not fit within the scope of the 
present review. 
 
Biofilms in respiratory tract infections 
Device-related infections 
In ventilator-associated pneumonia (VAP), biofilms are responsible for microbial 
persistence and impaired response to treatment. Biofilm formation within the first 24 hours 
after intubation has been demonstrated in 95% of endotracheal tubes. Pseudomonas 
aeruginosa and Acinetobacter baumannii are the most frequent bacteria that colonize the 
devices [4-6].  
 
Tissue-related infections 
Cystic fibrosis (CF) 
In CF, the incidence of bacterial lung infections is high since the mucoid polysaccharidic 
material that accumulates on the respiratory epithelium due to impaired mucociliary 
clearance in the bronchi of such patients favors biofilm formation. P. aeruginosa is the 
most common bacterial species involved in respiratory tract infection in CF patients and 
can be found in about half of all cases and in up to 70% of adults (Cystic Fibrosis 
Foundation Patient Registry. Annual data report 2013 Cystic Fibrosis Foundation, 
Bethesda, MD). The ability of P. aeruginosa to form biofilms is thought to be the primary 
reason for its survival in the CF lung, despite an exuberant inflammatory response and 
intensive antibiotic treatment [7,8]. Other pathogens such as Burkholderia cepacia 
complex, Staphylococcus aureus, Achromobacter xylosoxidans, and Stenotrophomonas 
maltophilia have also been identified in CF and are related to biofilm formation [9]. 
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Chronic obstructive pulmonary disease (COPD) 
A role of biofilms in patients with COPD has not been directly demonstrated but has been 
hypothesized considering the evidence indicating that the airways of these patients are 
frequently colonized by pathogens such as Haemophilus influenzae, Moraxella catarrhalis, 
and Streptococcus pneumoniae. COPD is characterized by frequent exacerbations and 
resistance to antibiotics. Even if direct evidence of biofilms in vivo is lacking, biofilms may 
reasonably be considered to be involved in the vicious cycle of infection/inflammation 
leading to disease progression in patients with COPD [10-12]. However, the role of 
biofilms in acute exacerbations needs to be further investigated (i.e. acute episodes 
caused by new strains or species compared to those accounting for chronic colonization). 
 
Non-cystic fibrosis bronchiectasis 
In bronchiectasis not due to CF, infections cause a change in the muscular and elastic 
components of the bronchial wall, which become distorted and enlarged. Airways slowly 
become unable to clear mucus, leading to serious lung infections that in turn cause more 
damage to bronchi. Biofilm formation has recently been demonstrated in vivo and is 
assumed to play a relevant role in the pathophysiological cascade of this disease [13-15]. 
Bacterial biofilm formation by P. aeruginosa or Klebsiella pneumoniae is common in 
bronchiectasis and could be an important factor that makes infections in bronchiectasis 
intractable. Other pathogens such as Veilonella sp., Prevotella sp. and Neisseria sp. have 
also been recently identified in patients with bronchiectasis [16,17]. 
 
Bronchitis  
Protracted bacterial bronchitis may be caused by chronic infections of the airways. 
Especially in children, the condition appears to be secondary to impaired mucociliary 
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clearance that creates an environment favorable for bacteria to become established, often 
in the form of biofilms [18]. The most commonly involved bacteria include H. influenzae 
(30-70%), S. pneumonia, and M. catarrhalis. 
 
Upper respiratory infections 
In otitis media, infections are due to both respiratory viruses and bacteria such as S. 
pneumonia (25-40%), non-capsulated H. influenzae (25-40%), M. catarrhalis (20%), 
Streptococcus pyogenes, and S. aureus (<10%), causing the appearance of polymicrobial 
biofilms [19-21]. Biofilms were identified in the sinus tissues of 72% of patients affected by 
chronic rhinosinusitis; the cultured organisms identified included S. aureus (50%), H. 
influenzae (28%), P. aeruginosa (22%), and fungi (22%). The presence of bacterial 
biofilms was strongly associated with persistent mucosal inflammation after endoscopic 
sinus surgery [22]. 
 
Biofilm development and functioning  
Five stages have been identified in biofilm development (Fig. 1). Early attachment is the 
first reversible stage: planktonic microbial cells adhere to the surface through weak, 
reversible van der Waals forces. If the process progresses, the early attachment is 
followed by irreversible late attachment where bacteria firmly attach to the surface through 
fimbrial and nonfimbrial adhesins and begin producing extracellular polymeric substances 
(EPS). Next, early-stage biofilms (third stage: maturation stage I) take form that consist of 
microcolonies immersed in EPS. When the biofilm matures (maturation stage II), it is 
characterized by microcolonies separated by open water channels that act as a primitive 
circulatory system. The mature biofilm begins to release planktonic cells and bacterial 
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aggregates (septic emboli) in the dispersion stage. 
 
Fig. 1. Stages of biofilm development. Each stage in the diagram has been paired with a photomicrograph of a 
developing Pseudomonas aeruginosa biofilm. Adapted from Davies [3] Copyright © 2003, Rights Managed by 
Nature Publishing Group 
This complex process relies on the ability of bacteria to function cooperatively through a 
cell-cell communication process called quorum sensing. Bacterial gene expression is 
regulated by bacterial density leading to either an enhancement or a decrease of their 
virulence factors [2].  
Due to their nature, biofilms are more resistant than planktonic cells to host defenses and 
antibiotics. Resistance to host defenses (phagocytes, complement and antibodies) is 
related to the presence of the EPS, which protect bacteria growing in the biofilm from 
phagocytes and humoral effectors [2,3,20]. Resistance to antibiotics is due to several 
factors including: i) a reduced penetration of drugs across the EPS matrix (demonstrated 
for some antibiotics that may actually be trapped by the EPS matrix, such as 
glycopeptides) [2,3,20]; ii) the physiological state of vegetative cells growing in the biofilm 
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(slow growth, anaerobic environment) that may render them less susceptible to some 
antibiotics (e.g. beta-lactams, aminoglycosides) [2,3,20]; iii) the presence of persister cells 
that, due to their state, are highly resistant to antibiotics and can subsequently regenerate 
vegetative cells within the biofilm [2,3,20].  
Anti-biofilm strategies may act by preventing bacterial adhesion (e.g. modifying roughness 
and physicochemical properties of biomaterials), impairing survival of the attached biofilm 
(e.g. using surfaces covered with Cu/Ag nanoparticles, antibiotics, or other antimicrobial 
agents), inhibiting the quorum-sensing response that is essential to biofilm formation, or 
disrupting the formed biofilm (using enzymes that degrade the matrix such as dispersin, 
DNase I) [2]. A very promising perspective, although still at an early stage of development, 
is the use of substances that are active against persister cells or that sensitize these cells 
to antimicrobial agents [2,23]. 
In respiratory tract infections many strategies have been developed. Antibiotics that 
penetrate the biofilm matrix and have a bactericidal rather than bacteriostatic mode of 
action can be useful. Combined antibiotic therapies seem to be better than monotherapy, 
and high dosages appear to be necessary to disrupt biofilms.  
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Fig. 2. Antibiofilm strategies. EPS=extracellular polymeric substances; ETT=endotracheal tubes; QS=quorum sensing. 
Adapted from Lebeaux et al. [2]. Copyright © 2014, American Society for Microbiology. All Rights Reserved. 
However, antibiotics alone seem unable to resolve the problem of biofilm infections, not 
only because of biofilm resistance, but also because of dispersion limitations posed by the 
biofilm extracellular matrix [2,24,25]. Apart from antimicrobials, several different 
compounds have been investigated in vitro for their potential to reduce biofilm formation. 
For example, non-steroidal anti-inflammatory drugs (NSAIDs) and mucolytics have been 
shown to have inhibitory effects on biofilm production [26-28]. 
 
The role of N-acetylcyseine against biofilms 
In vitro studies 
In vitro studies have indicated a potential role of NAC as an anti-biofilm agent. In fact, NAC 
has been reported to have antimicrobial activity against different microorganisms, and has 
been suggested to play a role in the various steps of biofilm formation: adhesion to inert 
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and living surfaces, matrix production and organization, and dispersal of preformed 
biofilms (see below). 
The ability of NAC to interfere with biofilm formation was first demonstrated by Pérez-
Giraldo and colleagues in 1997 [29]. In that investigation, the authors evaluated the effects 
of different NAC concentrations on bacterial growth and biofilm formation in cultures of 
Staphylococcus epidermidis. This study reported a concentration-related decrease in 
biofilm formation (at concentrations >0.25 mg/ml); furthermore, the inhibitory effect of 2 
mg/ml of NAC on matrix formation was demonstrated by electron microscopy. 
Since then, many other studies have demonstrated the efficacy of NAC in reducing biofilm 
formation induced by a variety of microorganisms (including Gram-negative and Gram-
positive bacteria, and yeasts), and shown its ability to impair matrix architecture and 
promote disruption of biofilm. Table 1 reports a selection of publications on these topics.  
Table 1. In vitro studies demonstrating anti-biofilm activity of NAC against bacterial and fungal 
pathogens. 
Pathogens examined Reference NAC concentrations tested (mg/ml) 
Gram-negative bacteria 
Escherichia coli El Feki et al., 2009 [30] 2 and 4 
 Marchese et al., 2003 [31] range 0.007-8 
Klebsiella pneumoniae Mohsen et al., 2015 [32] 2.5 
 Aslam and Darouiche, 2011 [33]  80 
 El Feki et al., 2009 [30] 2 and 4 
 Aslam et al., 2007 [34] 80 
 Olofsson et al., 2003 [35] range 0.25-2 
Enterobacter cloacae Aslam and Darouiche, 2011 [33] 80 
 Olofsson et al., 2003 [35] range 0.25-2 
Proteus spp. Mohsen et al., 2015 [32] 2.5 
 El Feki et al., 2009 [30] 2 and 4 
Pseudomonas aeruginosa Mohsen et al., 2015 [32] 2.5 
 Lea et al., 2014 [36] 12.5 
 Drago et al., 2013 [37] range 3-24 
 Aslam and Darouiche, 2011 [33]  80 
 Zhao et al., 2010 [38] range 0.5-10 
 El Feki et al., 2009 [30] 2 and 4 
Pseudomonas mendocina Olofsson et al., 2003 [35] range 0.25-2 
Acinetobacter baumannii Olofsson et al., 2003 [35] range 0.25-2 
Prevotella intermedia Moon et al., 2015 [39] range 0.375-3 
Gram-positive bacteria 
Staphylococcus aureus Mohsen et al., 2015 [32] 20 
 Drago et al., 2013 [37] range 6-24 
 Aslam and Darouiche, 2011 [33] 80 
 El Feki et al., 2009 [30] 2 and 4 
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One of these studies investigated the effect of NAC on biofilm formation and dispersal with 
a collection of clinical isolates of P. aeruginosa [38], which are known to be among the 
most important opportunistic pathogens that are responsible for biofilm-associated chronic 
respiratory colonization in patients with cystic fibrosis, COPD, and bronchiectasis. The 
results showed that NAC had some antimicrobial activity against planktonic cultures 
(minimum inhibitory concentrations [MIC] for the majority of isolates were ≤40 mg/ml). 
Mature biofilms of P. aeruginosa PAO-1 expressing a green fluorescent protein could be 
detached from glass cover slips at NAC concentrations as low as 0.5 mg/ml, as shown by 
confocal laser scanning microscopy. Using the dimethylthiazol diphenyltetrazolium 
bromide assay for determining viability of biofilm cells, the authors observed a dose-
dependent dispersal of mature biofilms formed by clinical isolates, despite the low 
concentrations of NAC tested (i.e. 0.5−2.5 mg/ml), and a synergistic interaction with 
ciprofloxacin. In addition, EPS production by P. aeruginosa was found to decrease by 27% 
and 44% at NAC concentrations of 0.5 mg/ml and 1 mg/ml, respectively. Recently, NAC 
was also demonstrated to significantly potentiate the efficacy of photodynamic therapy 
against S. aureus biofilms [48]. 
Despite the efficacy of NAC in association with antibiotics in some infections (i.e. urinary 
tract infections, device related infections) [33], few studies to date have been focused on 
 Aslam et al., 2007 [34] 80 
 Roveta et al., 2004 [40] 8 
 Bozzolasco et al., 2002 [41] range 0.007-8 
Staphylococcus epidermidis Leite et al., 2013 [42] 4 and 40 
 Kirmusaoğlu et al., 2012 [43] 0.03, 0.12, 0.5, and 2 
 Gomes et al., 2012 [44] 4 and 40 
 Aslam and Darouiche, 2011[33] 80 
 El Feki et al., 2009 [30] 2 and 4 
 Venkatesh et al., 2009 [45] range 0.5-32 
 Aslam et al., 2007 [34] 80 
 Perez-Giraldo et al., 1997 [29] range 0.003-8 
Enterococcus faecalis Quah et al., 2012 [46] range 12.5-50 
Yeast 
Candida albicans El-Baky et al., 2014; [47] range 0.312-40 
 Venkatesh et al., 2009 [45] range 0.5-32 
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biofilm-associated respiratory tract infections. In particular, Lea and colleagues [36] 
evaluated the effects of ciprofloxacin alone, ciprofloxacin + dexamethasone, NAC alone, 
and NAC + ciprofloxacin on 15 strains of P. aeruginosa isolated from patients with 
suppurative otitis media. While P. aeruginosa strains grew in the presence of ciprofloxacin 
+ dexamethasone and ciprofloxacin alone, no growth was found in the sessile or 
planktonic state among all 15 strains when NAC (≥ 5 mg/ml) was used either alone or in 
combination with ciprofloxacin. Another study [49] assessed the ability of 11 
pneumococcal strains (serotypes 3, 6B, 9V, 19F, and 23F) to form biofilms on polystyrene 
plates. Human serum albumin at 25,000 µg/ml and ibuprofen at 128 µg/ml both 
significantly reduced biofilm formation in 7 and 5 strains, respectively. Amoxicillin, 
erythromycin, and levofloxacin at concentrations above the MIC were very active against 
planktonic cells of 3 strains, but less or no active against biofilms. NAC alone had little 
activity against planktonic and sessile cultures, but when combined with the 3 antibiotics, a 
slightly enhanced activity against biofilms was observed in some strains. 
Some in vitro studies have also demonstrated the ability of NAC to affect adherence to 
respiratory epithelial cells of relevant respiratory pathogens [50,51]. Riise and colleagues 
[50] studied the effects of four compounds (NAC, lidocaine, hydrocortisone, and 
terbutaline) on bacterial adherence of oropharyngeal epithelial cells after short-term 
exposure and long-term incubation. S. pneumoniae and H. influenzae were the target 
bacteria. Following short-term exposure, NAC had an inhibitory effect on H. influenzae 
adhesion and was seen to be effective in inhibiting adherence even after long-term 
incubation. Both NAC and hydrocortisone lowered adherence of both strains in a 
concentration-dependent manner. NAC was also effective at inhibiting bacterial adhesion 
in the majority of H. influenzae (3 of 4) and all S. pneumoniae (n=3) strains. Zengh and 
colleagues demonstrated a significant reduction in the attachment to human pharyngeal 
epithelial cells by M. catarrhalis after exposure to mucoregulating drugs, including NAC 
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[51]. In this study, three strains of M. catarrhalis isolated from sputum of patients with 
respiratory infections were treated with NAC or S-carboxymethylcysteine and their ability 
to attach to pharyngeal epithelial cells was measured thereafter. A statistically significant 
reduction in attachment for both drugs was seen that was concentration-dependent. 
Taken together, in vitro studies suggest that NAC has a promising anti-biofilm activity. The 
mechanisms accounting for the antimicrobial and anti-biofilm activity of NAC, however, are 
still largely unknown and deserve further investigation to fully understand the potential for 
NAC in the management of biofilm-related infections. It has been suggested that the 
antimicrobial activity of NAC could be related to: i) competitive inhibition of cysteine 
utilization; ii) reaction of the NAC sulfhydryl group with bacterial proteins; and iii) 
perturbation of the intracellular redox equilibrium with potential indirect effects on cell 
metabolism and intracellular signal transduction pathways [35,38]. The perturbation of 
microbial physiology induced by NAC might, in turn, represent the key factor accounting 
for NAC-mediated inhibition of biofilm formation, since the processes leading to the switch 
from planktonic to sessile mode of growth are known to be controlled by complex 
regulatory networks [2]. The reported activity of NAC in promoting dispersal of preformed 
biofilms could be related either to perturbation of microbial physiology or to a direct effect 
of NAC in affecting biofilm matrix architecture (e.g. by chelation of calcium and magnesium 
or interaction with crucial components in the matrix) [35,38]. 
The multifactorial activity of NAC against microbial biofilms that has been hypothesized 
represents a strength for its potential use as an anti-biofilm agent. In particular, if further 
studies reinforce the available data, NAC may indeed be a promising candidate for 
prevention of biofilm formation and for potentiating conventional anti-biofilm treatments 
(including antimicrobial drugs and photodynamic therapy approaches). In addition, the 
non-antibiotic nature of NAC and the relevance of biofilms in many technical systems (e.g. 
paper mills) have raised a multidisciplinary interest for this molecule [35,52]. In this 
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perspective, further in vitro studies on this molecule are warranted in order to overcome 
important knowledge gaps and try to understand some apparent inconsistences in the 
available data, which are possibly related to the complex and still unclear mechanisms of 
NAC activity and to the difficulties and lack of standardization of in vitro biofilm models. 
 
Clinical studies 
Most studies have been conducted using oral or intramuscular NAC formulations. 
Cystic fibrosis 
The role of NAC in CF is still debated: a recent review [53] on the use of thiol derivates 
such as NAC concluded that there was not enough evidence to support the use of these 
compounds in clinical practice, but further studies were encouraged. Recently, Skov and 
colleagues [54] evaluated the effect of 4 weeks of treatment with oral NAC (2400 mg/day 
divided into two doses) on biochemical parameters of oxidative stress in an open-label, 
controlled, randomized trial on 21 patients (11 patients in the NAC group and 10 in the 
control group). Significantly decreased levels of oxidized vitamin C and increased vitamin 
C levels were seen in the NAC group; this group also had an improvement, though not 
significant, in lung function. 
In another study [55], 70 CF subjects received NAC or placebo orally three times daily for 
24 weeks. Oral NAC (900 mg x 3) maintained stable or slightly increased lung function in 
the treated group, while the control group showed a reduction in spirometric parameters. 
However, no change was observed in selected biomarkers of neutrophilic inflammation. 
These promising preliminary results suggest that further studies are required to better 
understand the role of NAC in treating patients with CF.  
 
COPD and chronic bronchitis 
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The role of NAC in preventing exacerbations of patients with COPD and chronic bronchitis 
has been the basis of a recent meta-analysis by Cazzola and colleagues [56]. From the 
data of 13 studies (of 48 eligible full text articles), the records of 4155 COPD patients 
(1933 treated with NAC and 2222 placebo or control) were analyzed. It was seen that 
patients treated with NAC had a decreased risk of exacerbations of chronic bronchitis or 
COPD, but the effect was higher in patients with an absence of airway obstruction. NAC 
was well tolerated and the risk of adverse effects was not significantly higher at the higher 
dose. Furthermore, the data showed that in the case of airway obstruction, higher doses 
(≥1200 mg per day) are needed to prevent exacerbations[51, 57], while regular doses (600 
mg per day) are sufficient in patients with chronic bronchitis. [58,59] 
A multicenter double blind study [60] on 180 patients with acute bronchitis, tracheo-
bronchitis, or acute exacerbations of chronic bronchitis compared the effects of 
thiamphenicol glycinate acetylcysteinate (TGA;n=92) and thiamphenicol glycinate (TG; 
n=88), both administered by aerosol. Both groups received the equivalent of 500 mg of 
thiamphenicol. Symptoms improved in both groups in terms of reduced frequency and 
cough severity and difficulties in expectoration. Furthermore, TGA was significantly more 
effective in eliminating cough within 6 days of treatment (82% versus 65%). Treatment 
efficacy was judged as “very good” (the maximum rating) by physicians in 37% of TGA-
treated patients and in 28% of TG-treated patients. Both treatments were well tolerated. 
 
Bronchiectasis 
In bronchiectasis, intervention should ideally target bacterial colonization, airway 
inflammation, and impaired mucociliary clearance at the same time. NAC seems to be 
useful in this latter process, but the evidence to date is not sufficiently supported by clinical 
studies [15,61]. 
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Other airway infections 
A large study by Serra and colleagues [62] enrolled 398 patients (age 18−75 years) with 
recurrent infections of the upper airways (rhinosinusitis, pharyngotonsillitis, and acute otitis 
media), and assessed the effect of TGA in 149 patients versus other oral antibiotics. TGA 
was administered by aerosol (500 mg ½ ampoule daily for 6−10 days); antibiotics used in 
other groups (amoxicillin/clavulanate, cefixime, cefaclor, clarithromycin, levofloxacin, 
moxifloxacin, or telithromycin) were administered orally in accordance with the standards 
of the trial center. The etiological agents isolated included S. pyogenens (up to 75% in 
pharyngotonsillitis), S. pneumoniae (up to 50% in otitis), H. influenzae (up to 35% in 
rhinosinusitis), and M. catarrhalis (up to 20% in rhinosinusitis). The clinical results showed 
symptom disappearance in 88% of patients with pharyngotonsillitis, 91.7% in otitis media, 
and 87% of rhinosinusitis in patients treated with inhaled TGA. In patients treated with oral 
antibiotics, percentages of symptom resolution were generally lower, although the 
differences were not statistically significant. In patients with rhinosinusitis, topical NAC 
(nasal douche) associated with flunisolide has been demonstrated to be more effective 
than ambroxol plus flunisolide in terms of symptom improvement and number of 
exacerbations at 3 and 6 months. Moreover, the time to first exacerbation was significantly 
increased with NAC compared with ambroxol [63]. The results of this study confirm that 
NAC added to standard flunisolide treatment via atomized nasal douche is an effective 
strategy to break the vicious circle of recurrent acute rhinosinusitis and improve patients’ 
conditions for up to 6 months following the end of treatment (Fig. 3). 
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Fig. 3. Results of Kaplan-Meier analysis showing time to first exacerbation after stopping treatments in the study by 
Macchi et al. [60]  
Further evidence for the efficacy of NAC in rhinosinusitis comes from the review by Smith 
and colleagues [64] where TGA was shown to be effective in treating chronic rhinosinusitis 
and eradicating bacterial biofilms. 
 
Discussion 
In the respiratory infection field, the available data indicate that NAC has good antibacterial 
properties and suggest that this drug has the ability to interfere with biofilm formation and 
to disrupt biofilms. In vitro studies strongly support this assumption, although more clinical 
evidence is required. 
NAC is usually given orally, with several formulations and dosage forms available for both 
short- and long-term treatment of respiratory diseases, but an inhalation route might also 
be considered a practical option. In particular, topical NAC causes a clear mucolytic effect 
by passing into the mucus and changing its physiochemical properties. The use of topical 
drugs has the advantage to reach the right anatomical target, at high concentrations, thus 
avoiding that the drug is metabolized by liver and intestines.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Therefore, the use of topical NAC in respiratory airway diseases may help in clinical 
practice, not only because of its efficacy [60,62], but also because it can reach the 
anatomical target thus paving the way for enhanced antibiotic action within the lung. 
Furthermore, inhaled formulations of NAC have been demonstrated to be effective when 
used in association with antibiotics, possibly because of the ability of NAC to inhibit biofilm 
formation and cause biofilm disruption [28; 29; 43,30, 50]. The use of inhaled NAC may be 
limited by the individual susceptibility to bronchoconstriction because of its acidic 
properties however, this would not be the case of every patient therefore it is a therapeutic 
option to be considered case by case.   Furthermore, NAC may help antibiotics to 
penetrate biofilms, allowing improved accessibility to bacteria. 
Since NAC has been demonstrated to reduce bacterial attachment [51], it could also be 
considered as a prophylactic agent in respiratory infections where topical administration of 
the drug to the upper respiratory tract may be a choice even for patients where prevention 
of respiratory infections, rather than expectoration of sputum, is the primary reason for 
treatment. 
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HIGHLIGHTS 
 
Bacteria can exist as single, independent cells (planktonic) or can be organized into 
sessile aggregates called biofilms. Recent advances have demonstrated that biofilms 
account for most human infections and are related to exacerbation or relapse of 
symptoms. 
 
The observation that systemic antibiotics are not unequivocally effective in eradicating 
biofilms has led to an increased interest in non-antibiotic therapies. 
 
In the respiratory infection field, the available data indicate that NAC has good 
antibacterial properties and suggest that this drug has the ability to interfere with biofilm 
formation and to disrupt biofilms. In vitro studies strongly support this assumption, 
although more clinical evidence is required.  
 
The multifactorial activity of NAC against microbial biofilms that has been hypothesized 
represents strength for its potential use as an anti-biofilm agent. In particular, if further 
studies reinforce the available data, NAC may indeed be a promising candidate for 
prevention of biofilm formation and for potentiating conventional anti-biofilm treatments 
(including antimicrobial drugs and photodynamic therapy approaches). 
 
The inhalation route might be considered a practical option for NAC. In particular, topical 
NAC causes a clear mucolytic effect by passing into the mucus and changing its 
physiochemical properties. The use of topical drugs has the advantage to reach the right 
anatomical target, at high concentrations, thus avoiding that the drug is metabolized by 
liver and intestines.  
 
 
